Work

A phase I/II study of ixazomib (Ix) pomalidomide (POM) dexamethasone (DEX) in relapsed refractory (R/R) multiple myeloma: Initial results.

Year: 2016

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2016.34.15_suppl.8008

Authors: Amrita Y. Krishnan, Prashant Kapoor, Joycelynne Palmer, Shaji Kumar, Sagar Lonial, Myo Htut, Chatchada Karanes, Nitya Nathwani, Michael Alan Rosenzweig, Firoozeh Sahebi, George Somlo, Lupe Duarte, Stephen J. Forman, Jesus G. Berdeja

Institutions: City Of Hope National Medical Center, Mayo Clinic, Winship Cancer Institute, City of Hope, Kaiser Permanente, Sarah Cannon

Language: English

Topic: Multiple Myeloma Research and Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2890318115

Cites:

Cited by: 11

Related to: 10